Related Experiment Video

Updated: Mar 11, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.6K

Cervical Cancer Growth Is Regulated by a c-ABL-PLK1 Signaling Axis

Xu Yang1, Gang Chen2, Wei Li3,4

  • 1State Key Laboratory of Proteomics, National Center for Protein Sciences, Beijing Institute of Radiation Medicine, Beijing, China.

Cancer Research
|December 1, 2016
PubMed

Insights

The nonreceptor tyrosine kinase c-ABL regulates cervical cancer growth by activating Polo-like kinase 1 (PLK1). Targeting this c-ABL-PLK1 axis offers a new strategy for treating cervical cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • The role of nonreceptor tyrosine kinase c-ABL in solid tumor growth remains unclear.
  • Polo-like kinase 1 (PLK1) is a critical regulator of mitosis.

Purpose of the Study:

  • To investigate the role of the c-ABL kinase in regulating cervical cancer progression.
  • To identify downstream effectors of c-ABL in cervical cancer.

Main Methods:

  • Investigated the interaction and phosphorylation of PLK1 by c-ABL in cervical cancer cells.
  • Assessed the impact of c-ABL on PLK1 ubiquitination, degradation, and activity.
  • Examined c-ABL and PLK1 expression levels in human cervical carcinoma tissues.
  • Evaluated the therapeutic potential of combined c-ABL and PLK1 inhibition in a murine xenograft model.

Main Results:

  • c-ABL directly phosphorylates PLK1, inhibiting its degradation and enhancing its activity.
  • Both c-ABL and PLK1 are overexpressed in cervical cancer tissues.
  • PLK1 tyrosine phosphorylation levels correlate with patient survival.
  • Combined inhibition of c-ABL and PLK1 demonstrated additive effects on tumor growth inhibition in vivo.

Conclusions:

  • The c-ABL-PLK1 signaling axis is a key driver of cervical cancer growth.
  • The c-ABL-PLK1 axis serves as a potential prognostic biomarker for cervical cancer.
  • Targeting the c-ABL-PLK1 pathway represents a promising therapeutic strategy for cervical cancer.

More Related Videos

Quantitative PCR-based Assay to Measure Sonic Hedgehog Signaling in Cellular Model of Ciliogenesis07:26

Quantitative PCR-based Assay to Measure Sonic Hedgehog Signaling in Cellular Model of Ciliogenesis

Published on: January 31, 2025

1.1K
Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer04:20

Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer

Published on: February 9, 2024

1.5K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
3.5K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.1K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.7K